Rituximab biosimilar - Bio Sidus S.A.
Latest Information Update: 16 Aug 2013
At a glance
- Originator Bio Sidus S.A.
- Developer Biosidus S.A.
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Immunological disorders; Non-Hodgkin's lymphoma; Transplant rejection
Most Recent Events
- 15 Aug 2013 Investigation in Immunological disorders in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Transplant rejection (prevention) in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Non-Hodgkin's lymphoma in Argentina (Parenteral)